Adv Colloid Interface Sci 2021 May 1;294:102407. Epub 2021 May 1.
Harangoutte Institute, 68160 Ste Croix-aux-Mines, France.
After the protocol-related indecisive clinical trial of Oxygent, a perfluorooctylbromide/phospholipid nanoemulsion, in cardiac surgery, that often unduly assigned the observed untoward effects to the product, the development of perfluorocarbon (PFC)-based O nanoemulsions ("blood substitutes") has come to a low. Yet, significant further demonstrations of PFC O-delivery efficacy have continuously been reported, such as relief of hypoxia after myocardial infarction or stroke; protection of vital organs during surgery; potentiation of O-dependent cancer therapies, including radio-, photodynamic-, chemo- and immunotherapies; regeneration of damaged nerve, bone or cartilage; preservation of organ grafts destined for transplantation; and control of gas supply in tissue engineering and biotechnological productions. PFC colloids capable of augmenting O delivery include primarily injectable PFC nanoemulsions, microbubbles and phase-shift nanoemulsions. Read More